Labiotech

2 weeks ago | labiotech.eu | Clara Fernandez |Clara Fernández

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*NameThis field is for validation purposes and should be left unchanged. Since the approval of the first-ever gene therapy for blindness, there has been a wave of biotechs developing gene therapy treatments with the potential to cure different forms of genetic vision loss.

2 weeks ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*CommentsThis field is for validation purposes and should be left unchanged. For the first time in 50 years, a new antibiotic has been created to tackle a drug-resistant bacteria that causes serious infections like pneumonia and sepsis.

3 weeks ago | labiotech.eu | Jules Adam

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*PhoneThis field is for validation purposes and should be left unchanged. CRISPR-Cas9 has reshaped what’s possible in genetic engineering.

3 weeks ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*PhoneThis field is for validation purposes and should be left unchanged. We’re nearly halfway through 2025, and like clockwork, the American Society of Clinical Oncology (ASCO) annual summit took place from the 30th of May to the 3rd of June in Chicago this year.

3 weeks ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*EmailThis field is for validation purposes and should be left unchanged. The month of May was a quieter one on the deals front compared to the past few months this year. Still, biopharmas got together to fuel the RNA and small molecule spaces.